Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F22%3A00013409" target="_blank" >RIV/00023736:_____/22:00013409 - isvavai.cz</a>

Alternative codes found

RIV/65269705:_____/22:00076133 RIV/00216224:14110/22:00128094

Result on the web

<a href="https://doi.org/10.1038/s41375-022-01607-z" target="_blank" >https://doi.org/10.1038/s41375-022-01607-z</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41375-022-01607-z" target="_blank" >10.1038/s41375-022-01607-z</a>

Result language

angličtina

Original language name

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Original language description

Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the use of secondary, lyophilized cell-based BCR::ABL1 reference panels traceable to the World Health Organization primary reference material to standardize and validate local laboratory tests. Panels were used to assign and validate conversion factors (CFs) to the International Scale and assess the ability of laboratories to assess deep molecular response (DMR). The study also explored aspects of internal quality control. The percentage of EUTOS reference laboratories (n = 50) with CFs validated as optimal or satisfactory increased from 67.5% to 97.6% and 36.4% to 91.7% for ABL1 and GUSB, respectively, during the study period and 98% of laboratories were able to detect MR4.5 in most samples. Laboratories with unvalidated CFs had a higher coefficient of variation for BCR::ABL1(IS) and some laboratories had a limit of blank greater than zero which could affect the accurate reporting of DMR. Our study indicates that secondary reference panels can be used effectively to obtain and validate CFs in a manner equivalent to sample exchange and can also be used to monitor additional aspects of quality assurance.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia

ISSN

0887-6924

e-ISSN

—

Volume of the periodical

36

Issue of the periodical within the volume

7

Country of publishing house

GB - UNITED KINGDOM

Number of pages

9

Pages from-to

1834-1842

UT code for WoS article

000802314200002

EID of the result in the Scopus database

2-s2.0-85130820056